Literature DB >> 18525434

Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city.

Carlo V Caballero-Uribe1, Juan G Acosta-Velez, Eder A Hernandez-Ruiz, Fernando M Andrade Rodado, Martha Peñuela-Epalza.   

Abstract

OBJECTIVES: To examine current practices for the diagnosis and therapy for glucocorticoid-induced osteoporosis (GIOP) in patients under treatment with corticosteroids at outpatient clinics of rheumatologists in a Colombian Caribbean city.
METHODS: All patients noted to be using of glucocorticoids (GC) on an index consult from February to May 2004 were included in a descriptive cross sectional study. Criteria for inclusion of patients were to have had, at least, one previous visit to the service. We evaluated the study population for osteoporosis diagnosis, procedures, and treatment.
RESULTS: Of the 121 patients included, 103 (85.1%) were female and 18 (14.9%) were male; 76 patients (62.8%) were under 50 years, and 45 (37.2%) were over 50 years. Main reasons for corticosteroid use were rheumatoid arthritis in 68 patients (56.2%) and systemic lupus erythematous (SLE) in 31 patients (25.6%). Diagnostic testing for osteoporosis was reported on 50.1% of patients. Peripheral dual energy x-ray absorptiometry was the most frequently used method (52.6%). Therapeutic agents for GIOP were used in 96 patients (79.3%), with Calcium plus Vitamin D (55.2%) the principal treatments prescribed.
CONCLUSIONS: We found similar rates of diagnosis and treatment for GIOP to those reported in North America and Europe, although in this study treatment was mainly with calcium and vitamin D. There was a statistically significant relationship between being studied with any diagnostic method and being treated for GIOP. There may be undertreatment for GIOP in Latin America. Local interventions to improve care for patients in chronic use of steroids are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525434     DOI: 10.1097/RHU.0b013e31816b1931

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  3 in total

1.  Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.

Authors:  U Massafra; S Migliaccio; C Bancheri; F Chiacchiararelli; F Fantini; F Leoni; L S Martin; A Migliore; B Muccifora; C Napolitano; R Pastore; A Ragno; S Ronzoni; M Rotondi; M Tibaldi; P Villa; V Vinicola; E D'Erasmo; P Falaschi; G Minisola
Journal:  J Endocrinol Invest       Date:  2012-03-06       Impact factor: 4.256

2.  Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica.

Authors:  Antonio Naranjo; Rubén López; Blanca García-Magallón; Laura Cáceres; Félix Francisco; Mercedes Jiménez-Palop; Soledad Ojeda-Bruno
Journal:  Rheumatol Int       Date:  2014-04-12       Impact factor: 2.631

Review 3.  Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.

Authors:  Chu-Han Cheng; Li-Ru Chen; Kuo-Hu Chen
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.